Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells
View abstract on PubMed
Summary
This summary is machine-generated.Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists show promise in preventing vascular graft rejection by inhibiting human T cell responses. These findings suggest a potential new treatment for transplant rejection.
Area Of Science
- Immunology
- Transplantation Biology
- Pharmacology
Background
- Peroxisome proliferator-activated receptor-gamma (PPARγ) ligands possess anti-inflammatory properties.
- Allogeneic T cell responses drive vascular graft rejection, leading to graft loss.
- Rodent studies suggest PPARγ agonists may prevent vascular rejection, but human responses remain unclear.
Purpose Of The Study
- To investigate the effects of PPARγ agonists on human vascular graft rejection.
- To determine the role of PPARγ in human T cell responses to allogeneic vascular cells.
Main Methods
- A human vascular graft rejection model in immunodeficient mice using human artery and allogeneic human peripheral blood mononuclear cells.
- Administration of PPARγ agonists (15-deoxy-prostaglandin-J(2), ciglitazone, pioglitazone) and a PPARγ antagonist (GW9662).
- Assessment of intimal thickening, T cell infiltration, inflammatory cytokine levels, and in vitro T cell proliferation and migration.
Main Results
- PPARγ agonists significantly reduced intimal expansion, T cell infiltration, and inflammatory cytokine levels.
- The PPARγ antagonist GW9662 reversed the protective effects of PPARγ agonists.
- In vitro, pioglitazone inhibited alloantigen-induced T cell proliferation and transendothelial migration.
Conclusions
- PPARγ agonists effectively inhibit allogeneic human memory T cell responses in a vascular graft rejection model.
- PPARγ agonists represent a potential therapeutic strategy for treating vascular graft rejection.